Jump to section
Their mission is to empower scientists to increase the scope and scale of their experiments.
For bioscientists, quantifying multiple proteins at the same time is expensive and time-consuming. Nomic solves this problem with its proteomic platform, nELISA.
First launched as nplex biosciences, Nomic has since rebranded, fueled by an impressive $17 million in funding. This has allowed the company to accelerate its research considerably. Nomic works with a range of top-tier pharma companies and research institutes, which is testament to the demand for their product.
Nomic will need to continue to draw top talent to their ranks, and to attract even more funding, if they are to research and roll out their product effectively.
Freddie
Company Specialist at Welcome to the Jungle
Sep 2024
$42m
SERIES B
Dec 2021
$17m
SERIES A
This company has top investors
Milad Dagher
(CEO)Holds a PhD in Biological and Biomedical Engineering from McGill.
Jeff Munzar
(Head of Technology)Was previously CEO & Co-founder of Fetch Biosciences.